Expressed protein ligation uses self-splicing inteins to enable the production of site-specific protein conjugates. While widely used in research settings, less effort has been invested in developing an intein platform suitable for manufacturing of bioconjugate pharmaceuticals. We will present progress in engineering intein constructs to improve the expression and stability of the resulting proteins with the goal of making commercial use of this technology feasible.

Developing a bioconjugation platform for hybrid modalities

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.